サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：非感染性黄斑浮腫治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤タイプ別、適応症別、投与経路別、流通チャネル別、地域別
市場調査レポート
商品コード
1410591

非感染性黄斑浮腫治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤タイプ別、適応症別、投与経路別、流通チャネル別、地域別

Non-infectious Macular Edema Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

出版日
ページ情報
英文 323 Pages
納期
2～5営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
非感染性黄斑浮腫治療の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤タイプ別、適応症別、投与経路別、流通チャネル別、地域別
出版日: 2024年01月10日
発行: Fairfield Market Research
ページ情報: 英文 323 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の非感染性黄斑浮腫治療市場の著しい開拓に光を当てた画期的な研究があります。糖尿病に関連する合併症の急増と、様々な地域における眼に関連する病気に対する意識の高まりが、黄斑浮腫に対する効果的な治療法に対する需要の高まりに拍車をかけています。この需要の急増により、市場では抗VEGF薬、副腎皮質ステロイド薬、免疫抑制薬、生物学的製剤などの治療選択肢が急増しています。抗VEGF療法は従来から市場を独占しており、予測期間中も高い市場シェアを維持すると予想されます。

しかし、抗VEGF薬市場は、抗VEGF薬に関連する潜在的な副作用に対する意識の高まりから、徐々に使用量が減少していくと予想されています。全身的な免疫調節治療により、抗VEGF薬への依存度は低下するものと思われます。特に、副腎皮質ステロイドは今後数年間で需要が急増すると予測されており、予測期間中に市場は飛躍的な成長が見込まれます。

黄斑浮腫治療用の硝子体内インプラントが最近承認されたことが、市場成長の起爆剤となっています。Eylea、Ozurdex、Iluvienという3つの新製品の導入により、特に北米では硝子体内注射薬の採用が増加しています。北米や欧州諸国では、2012年にルセンティスが発売されるまでは、硝子体内注射薬はあまり使用されておらず、レーザー光凝固療法が主な治療方法でした。

硝子体内注射療法の採用が増加しているのは、低用量で高い効果を示すコルチコステロイドインプラントを硝子体内注射で使用できるようになったためです。患者はますます硝子体内インプラントを使用するようになっており、黄斑浮腫治療の世界的需要を牽引しています。

免疫抑制療法は副腎皮質ステロイドと併用されることが多く、黄斑浮腫の治療において重要な役割を果たしています。これらの治療薬は通常、ステロイドの大量投与の必要性を減らすためにコルチコステロイドレジメンに追加されるか、ステロイド治療に十分な忍容性がない場合にステロイドを温存する薬剤として単独で使用されます。

市場が大きな成長の可能性を示す一方で、課題も残っています。多くの患者や眼科医が、抗VEGF薬やコルチコステロイド薬よりも代替治療を選択しています。糖尿病黄斑浮腫（DME）患者では、注射の打ち忘れによる治療スケジュールの不遵守が、不可逆的な損傷や永続的な視力喪失につながる可能性があります。

さらに、偽造薬や適応外薬は世界市場で容易に入手可能です。いくつかの大ヒット抗VEGF薬のバイオシミラーが発売されたことで、ブランド薬や特許薬の使用機会が減少し、市場にさらなる影響が及ぶと予想されます。

当レポートでは、世界の非感染性黄斑浮腫治療市場について調査し、市場の概要とともに、薬剤タイプ別、適応症別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 生産高と貿易統計、2018年～2023年

第4章 価格分析、2018年～2023年

第5章 世界の非感染性黄斑浮腫治療市場の見通し、2018年～2031年

  • 世界の非感染性黄斑浮腫治療市場の見通し、薬剤タイプ別、金額（100万米ドル）、数量（2018年～2031年）
  • 世界の非感染性黄斑浮腫治療市場の見通し、適応症別、金額（100万米ドル）、数量（2018年～2031年）
  • 世界の非感染性黄斑浮腫治療市場の見通し、投与経路、金額（100万米ドル）、数量（2018年～2031年）
  • 世界の非感染性黄斑浮腫治療市場の見通し、流通チャネル別、金額（100万米ドル）、数量（2018年～2031年）
  • 世界の非感染性黄斑浮腫治療市場の見通し、地域別、金額（100万米ドル）、数量（2018年～2031年）

第6章 北米の非感染性黄斑浮腫治療市場の見通し、2018年～2031年

第7章 欧州の非感染性黄斑浮腫治療市場の見通し、2018年～2031年

第8章 アジア太平洋の非感染性黄斑浮腫治療市場の見通し、2018年～2031年

第9章 ラテンアメリカの非感染性黄斑浮腫治療市場の見通し、2018年～2031年

第10章 中東・アフリカの非感染性黄斑浮腫治療市場の見通し、2018年～2031年

第11章 競合情勢

  • 製品と適応症のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競争力ダッシュボード
  • 企業プロファイル
    • Pfizer, Inc.
    • Novartis AG
    • F. Hoffman - La Roche Ltd.
    • AbbVie Inc
    • Bayer AG
    • Valeant Pharmaceuticals Inc
    • Alimera Sciences Inc
    • Clearside Biomedical, Inc

第12章 付録

目次

A groundbreaking study has shed light on a remarkable development in the global non-infectious macular edema treatment market. The surge in diabetes-related complications and increased awareness of eye-related ailments across various regions have fueled a growing demand for effective treatments for macular edema. This surge in demand has led to a proliferation of treatment options in the market, including Anti-VEGF, Corticosteroids, Immunosuppressants, Biologics, and more. Anti-VEGF treatments have traditionally dominated the market, and they are expected to maintain the highest market share during the forecast period.

Transition Away from Anti-VEGF Toward Corticosteroids

However, the Anti-VEGF market is anticipated to witness a gradual decline in usage due to heightened awareness of potential side effects associated with the drug. Systemic immunomodulatory treatment is poised to reduce reliance on Anti-VEGF medications. Notably, Corticosteroids are projected to experience an exceptional surge in demand in the coming years, with the market expected to grow at a stellar rate during the forecast period.

Intravitreal Implants and Immunosuppressants Triggering Market Growth

The recent approval of Intravitreal Implants for macular edema treatment has catalyzed market growth. The introduction of three new products - Eylea, Ozurdex, and Iluvien - has led to increased adoption of intravitreal medications, particularly in North America. Intravitreally injected medications were less commonly used in North America and European countries, where laser photocoagulation was the primary treatment method before the launch of Lucentis in 2012.

The rising adoption of Intravitreal therapies can be attributed to the availability of low-dose, high-efficacy corticosteroid implants for Intravitreal use. Patients are increasingly turning to Intravitreal implants, driving global demand for macular edema treatment.

Immunosuppressant Therapies Enhance Treatment Efficacy

Immunosuppressant therapies, often used in conjunction with corticosteroids, play a vital role in the treatment of macular edema. These therapies are typically added to corticosteroid regimens to reduce the need for high doses of systemic steroids or used independently as steroid-sparing agents when steroid treatment is not well-tolerated.

For example, three immunomodulators - methotrexate (Rheumatrex), azathioprine (Imuran), and mycophenolate mofetil (MMF, Cellcept) - have proven to be highly effective in achieving disease quiescence and are well-tolerated by patients. These immunosuppressants have emerged as efficient treatment options, driving demand in the global market for non-infectious macular edema treatment.

Challenges in the Global Macular Edema Market

While the market exhibits significant growth potential, challenges persist. Many patients and ophthalmologists opt for alternative treatments over Anti-VEGF and corticosteroids due to the repeated injections and high costs associated with these drugs. Non-compliance with treatment schedules, resulting in missed injections, can lead to irreversible damage and permanent vision loss in diabetic macular edema (DME) patients.

Additionally, counterfeit and off-label drugs are readily available in the global market. The launch of biosimilars for some blockbuster anti-VEGF agents is expected to further impact the market by reducing opportunities for branded and patented drugs.

Market Segmentation

Drug Type

  • Anti-VEGF
  • Corticosteroids
  • Immunosuppressant
  • Biologics
  • Others

Indication

  • Non-infectious Uveitic Macular Edema
  • Diabetic Macular Edema
  • Retinal Vein Occlusion with Macular Edema

Route of Administration

  • Oral
  • Parenteral
  • Topical

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
  • Latin America
  • Europe
  • Japan
  • MEA
  • APAC

Table of Contents

1. Executive Summary

  • 1.1. Global Non-infectious Macular Edema Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value and Volume, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Production Output and Trade Statistics, 2018 - 2023

  • 3.1. Global Non-infectious Macular Edema Treatment Market Production Output, by Region, Value (US$ Mn), 2018 - 2023
    • 3.1.1. North America
    • 3.1.2. Europe
    • 3.1.3. Asia Pacific
    • 3.1.4. Latin America
    • 3.1.5. Middle East and Africa

4. Price Analysis, 2018 - 2023

  • 4.1. Global Average Price Analysis, by Drug Type/ Material, US$ Per Unit, 2018 - 2023
  • 4.2. Prominent Factor Affecting Non-infectious Macular Edema Treatment Prices
  • 4.3. Global Average Price Analysis, by Region, US$ Per Unit

5. Global Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 5.1. Global Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Anti-VEGF
      • 5.1.1.2. Corticosteroids
      • 5.1.1.3. Immunosuppressant
      • 5.1.1.4. Biologics
      • 5.1.1.5. Others
  • 5.2. Global Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Non-infectious Uveitic Macular Edema
      • 5.2.1.2. Diabetic Macular Edema
      • 5.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 5.3. Global Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Oral
      • 5.3.1.2. Parenteral
      • 5.3.1.3. Topical
  • 5.4. Global Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Online Pharmacies
  • 5.5. Global Non-infectious Macular Edema Treatment Market Outlook, by Region, Value (US$ Mn) and Volume, 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. North America
      • 5.5.1.2. Europe
      • 5.5.1.3. Asia Pacific
      • 5.5.1.4. Latin America
      • 5.5.1.5. Middle East & Africa

6. North America Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 6.1. North America Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Anti-VEGF
      • 6.1.1.2. Corticosteroids
      • 6.1.1.3. Immunosuppressant
      • 6.1.1.4. Biologics
      • 6.1.1.5. Others
  • 6.2. North America Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Non-infectious Uveitic Macular Edema
      • 6.2.1.2. Diabetic Macular Edema
      • 6.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 6.3. North America Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Oral
      • 6.3.1.2. Parenteral
      • 6.3.1.3. Topical
  • 6.4. North America Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Online Pharmacies
  • 6.5. North America Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. U.S. Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.2. U.S. Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.3. U.S. Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.4. U.S. Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.5. Canada Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.6. Canada Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.7. Canada Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 6.5.1.8. Canada Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Europe Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 7.1. Europe Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Anti-VEGF
      • 7.1.1.2. Corticosteroids
      • 7.1.1.3. Immunosuppressant
      • 7.1.1.4. Biologics
      • 7.1.1.5. Others
  • 7.2. Europe Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Non-infectious Uveitic Macular Edema
      • 7.2.1.2. Diabetic Macular Edema
      • 7.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 7.3. Europe Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Oral
      • 7.3.1.2. Parenteral
      • 7.3.1.3. Topical
  • 7.4. Europe Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Online Pharmacies
  • 7.5. Europe Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Germany Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.2. Germany Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.3. Germany Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.4. Germany Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.5. U.K. Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.6. U.K. Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.7. U.K. Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.8. U.K. Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.9. France Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.10. France Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.11. France Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.12. France Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.13. Italy Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.14. Italy Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.15. Italy Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.16. Italy Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.17. Turkey Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.18. Turkey Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.19. Turkey Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.20. Turkey Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.21. Russia Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.22. Russia Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.23. Russia Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.24. Russia Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.25. Rest of Europe Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.26. Rest of Europe Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.27. Rest of Europe Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 7.5.1.28. Rest of Europe Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 8.1. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Anti-VEGF
      • 8.1.1.2. Corticosteroids
      • 8.1.1.3. Immunosuppressant
      • 8.1.1.4. Biologics
      • 8.1.1.5. Others
  • 8.2. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Non-infectious Uveitic Macular Edema
      • 8.2.1.2. Diabetic Macular Edema
      • 8.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 8.3. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Oral
      • 8.3.1.2. Parenteral
      • 8.3.1.3. Topical
  • 8.4. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Online Pharmacies
  • 8.5. Asia Pacific Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. China Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.2. China Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.3. China Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.4. China Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.5. Japan Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.6. Japan Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.7. Japan Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.8. Japan Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.9. South Korea Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.10. South Korea Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.11. South Korea Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.12. South Korea Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.13. India Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.14. India Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.15. India Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.16. India Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.17. Southeast Asia Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.18. Southeast Asia Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.19. Southeast Asia Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.20. Southeast Asia Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.21. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.22. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.23. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 8.5.1.24. Rest of Asia Pacific Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Latin America Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 9.1. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.1.1. Key Highlights
      • 9.1.1.1. Anti-VEGF
      • 9.1.1.2. Corticosteroids
      • 9.1.1.3. Immunosuppressant
      • 9.1.1.4. Biologics
      • 9.1.1.5. Others
  • 9.2. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.2.1. Key Highlights
      • 9.2.1.1. Non-infectious Uveitic Macular Edema
      • 9.2.1.2. Diabetic Macular Edema
      • 9.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 9.3. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.3.1. Key Highlights
      • 9.3.1.1. Oral
      • 9.3.1.2. Parenteral
      • 9.3.1.3. Topical
  • 9.4. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.4.1. Key Highlights
      • 9.4.1.1. Hospital Pharmacies
      • 9.4.1.2. Retail Pharmacies
      • 9.4.1.3. Online Pharmacies
  • 9.5. Latin America Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.1. Key Highlights
      • 9.5.1.1. Brazil Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.2. Brazil Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.3. Brazil Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.4. Brazil Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.5. Mexico Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.6. Mexico Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.7. Mexico Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.8. Mexico Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.9. Argentina Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.10. Argentina Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.11. Argentina Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.12. Argentina Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.13. Rest of Latin America Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.14. Rest of Latin America Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.15. Rest of Latin America Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 9.5.1.16. Rest of Latin America Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 9.5.2. BPS Analysis/Market Attractiveness Analysis

10. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, 2018 - 2031

  • 10.1. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.1.1. Key Highlights
      • 10.1.1.1. Anti-VEGF
      • 10.1.1.2. Corticosteroids
      • 10.1.1.3. Immunosuppressant
      • 10.1.1.4. Biologics
      • 10.1.1.5. Others
  • 10.2. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Indication, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.2.1. Key Highlights
      • 10.2.1.1. Non-infectious Uveitic Macular Edema
      • 10.2.1.2. Diabetic Macular Edema
      • 10.2.1.3. Retinal Vein Occlusion with Macular Edema
  • 10.3. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.3.1. Key Highlights
      • 10.3.1.1. Oral
      • 10.3.1.2. Parenteral
      • 10.3.1.3. Topical
  • 10.4. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.4.1. Key Highlights
      • 10.4.1.1. Hospital Pharmacies
      • 10.4.1.2. Retail Pharmacies
      • 10.4.1.3. Online Pharmacies
  • 10.5. Middle East & Africa Non-infectious Macular Edema Treatment Market Outlook, by Country, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.1. Key Highlights
      • 10.5.1.1. GCC Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.2. GCC Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.3. GCC Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.4. GCC Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.5. South Africa Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.6. South Africa Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.7. South Africa Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.8. South Africa Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.9. Egypt Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.10. Egypt Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.11. Egypt Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.12. Egypt Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.13. Nigeria Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.14. Nigeria Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.15. Nigeria Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.16. Nigeria Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.17. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Drug Type, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.18. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Indication, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.19. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Route of Administration, Value (US$ Mn) and Volume, 2018 - 2031
      • 10.5.1.20. Rest of Middle East & Africa Non-infectious Macular Edema Treatment Market by Distribution Channel, Value (US$ Mn) and Volume, 2018 - 2031
    • 10.5.2. BPS Analysis/Market Attractiveness Analysis

11. Competitive Landscape

  • 11.1. Product vs Indication Heatmap
  • 11.2. Company Market Share Analysis, 2023
  • 11.3. Competitive Dashboard
  • 11.4. Company Profiles
    • 11.4.1. Pfizer, Inc.
      • 11.4.1.1. Company Overview
      • 11.4.1.2. Product Portfolio
      • 11.4.1.3. Financial Overview
      • 11.4.1.4. Business Strategies and Development
    • 11.4.2. Novartis AG
      • 11.4.2.1. Company Overview
      • 11.4.2.2. Product Portfolio
      • 11.4.2.3. Financial Overview
      • 11.4.2.4. Business Strategies and Development
    • 11.4.3. F. Hoffman - La Roche Ltd.
      • 11.4.3.1. Company Overview
      • 11.4.3.2. Product Portfolio
      • 11.4.3.3. Financial Overview
      • 11.4.3.4. Business Strategies and Development
    • 11.4.4. AbbVie Inc
      • 11.4.4.1. Company Overview
      • 11.4.4.2. Product Portfolio
      • 11.4.4.3. Financial Overview
      • 11.4.4.4. Business Strategies and Development
    • 11.4.5. Bayer AG
      • 11.4.5.1. Company Overview
      • 11.4.5.2. Product Portfolio
      • 11.4.5.3. Financial Overview
      • 11.4.5.4. Business Strategies and Development
    • 11.4.6. Valeant Pharmaceuticals Inc
      • 11.4.6.1. Company Overview
      • 11.4.6.2. Product Portfolio
      • 11.4.6.3. Financial Overview
      • 11.4.6.4. Business Strategies and Development
    • 11.4.7. Alimera Sciences Inc
      • 11.4.7.1. Company Overview
      • 11.4.7.2. Product Portfolio
      • 11.4.7.3. Financial Overview
      • 11.4.7.4. Business Strategies and Development
    • 11.4.8. Clearside Biomedical, Inc
      • 11.4.8.1. Company Overview
      • 11.4.8.2. Product Portfolio
      • 11.4.8.3. Financial Overview
      • 11.4.8.4. Business Strategies and Development

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Report Assumptions
  • 12.3. Acronyms and Abbreviations